BBOT director Peter Lebowitz files initial Form 3

BridgeBio Oncology Therapeutics, Inc. director Peter F. Lebowitz has filed an initial insider ownership report on Form 3.

Accepted by SEC EDGAR 03/26/2026 - 05:12 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. director Peter F. Lebowitz has filed an initial insider ownership report on Form 3. This filing establishes his status as a director of the company under insider reporting rules. The provided data show no reported transactions or derivative positions in this filing excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BridgeBio Oncology Therapeutics (BBOT) Form 3 for Peter F. Lebowitz show?

The Form 3 shows that Peter F. Lebowitz is a director of BridgeBio Oncology Therapeutics, Inc. The excerpt lists no stock transactions or derivative positions, serving primarily to establish his insider reporting status with the SEC.

Are there any stock purchases or sales reported for BBOT director Peter F. Lebowitz?

No stock purchases or sales are reported for Peter F. Lebowitz in this Form 3 excerpt. The transaction summary indicates zero buy, sell, acquire, dispose, and exercise counts, meaning no trading activity is disclosed here.

Does the BBOT Form 3 for Peter F. Lebowitz include any derivative securities?

The Form 3 excerpt shows no listed derivative securities for Peter F. Lebowitz. The derivativeSummary is empty and the derivativeTransactionCount is zero, indicating no options, warrants, or similar instruments are reported in this data.

What is the purpose of this BBOT Form 3 filing for Peter F. Lebowitz?

This Form 3 primarily establishes Peter F. Lebowitz as a director and therefore an insider of BridgeBio Oncology Therapeutics, Inc. It is an initial ownership report and, in this excerpt, does not detail any specific share or option holdings.

Does the BBOT Form 3 excerpt indicate any gifting or tax-withholding transactions?

No gifting or tax-withholding transactions are indicated in the excerpt. The transaction summary lists giftCount and taxWithholdingCount as zero, so no such movements of shares are reported for Peter F. Lebowitz here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lebowitz Peter F

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/24/2026

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Aaron Chan, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)